-
1Academic Journal
Συγγραφείς: O. M. Nesterova, Y. R. Lentsik, A. A. Vitik, E. D. Kosmacheva, V. I. Fetisova, M. N. Zamyatin, О. М. Нестерова, Ю. Р. Ленцик, А. А. Витик, Е. Д. Космачёва, В. И. Фетисова, М. Н. Замятин
Πηγή: Aterotromboz = Atherothrombosis; № 2 (2021); 76-86 ; Атеротромбоз; № 2 (2021); 76-86 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-2
Θεματικοί όροι: гемостаз, clinical case, atrial fibrillation, neutralization of anticoagulant effects, hemostasis, клинический пример, фибрилляция предсердий, нейтрализация антикоагулянтного эффекта
Περιγραφή αρχείου: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/257/279; Liew A., O’Donnell M., Douketis J. Comparing mortality in patients with atrial fibrillation who are receiving a directacting oral anticoagulant or warfarin: a meta-analysis of randomized trials. J Thromb Haemost. 2014;12(9):1419– 1424. https://doi.org/10.1111/jth.12651.; Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. https://doi.org/10.1016/S0140-6736(13)62343-0.; Wu C., Alotaibi G.S., Alsaleh K., Sean McMurtry M. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review. Thromb Res. 2014;134(3):627–632. https://doi.org/10.1016/j.thromres.2014.07.001.; Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561.; Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. https://doi.org/10.15829/1560-4071-2021-4594.; Печерина Т.Б., Ларионов М.В., Хан Д.С., Шпагина Л.А., Пудов Е.В., Барбараш О.Л. Опыт применения в России идаруцизумаба – специфического антагониста дабигатрана. Медицинский алфавит. 2020;1(19):29–38. https://doi.org/10.33667/2078-5631-2020-19-29-38.; Huisman M.V., Fanikos J. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. Am J Emerg Med. 2016;34(11S):46–51. https://doi.org/10.1016/j.ajem.2016.09.053.; Pollack C.V. Jr, Bernstein R., Dubiel R., Reilly P., Gruenenfelder F., Huisman M.V. et al. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ. 2017;20(5):435–442. https://doi.org/10.1080/13696998.2016.1273229.; Papachristos I.V., Giannoudis P.V. Proximal femur fractures in patients taking anticoagulants. EFORT Open Rev. 2020;5(10):699–706. https://doi.org/10.1302/2058-5241.5.190071.; You D., Xu Y., Ponich B., Ronksley P., Skeith L., Korley R. et al. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. Bone Joint J. 2021;103-B(2):222–233. https://doi.org/10.1302/0301-620X.103B2.BJJ-2020-0583.R2.; Fanikos J., Murwin D., Gruenenfelder F., Tartakovsky I., França L.R., Reilly P.A. et al. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thromb Haemost. 2020;120(1):27–35. https://doi.org/10.1055/s-0039-1695771.; Levy J.H., van Ryn J., Sellke F.W., Reilly P.A., Elsaesser A., Glund S. et al. Dabigatran Reversal with Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. Ann Surg. 2021;274(3):e204-e211. https://doi.org/10.1097/SLA.0000000000003638.; Рыбачков В.В., Кабанов Е.Н., Тевяшов А.В., Абакшин Н.С. О хирургической тактике при ущемленных грыжах. Хирургия. Журнал им. Н.И. Пирогова. 2011;(12):55–58. Режим доступа: https://www.mediasphera.ru/issues/khirurgiya-zhurnal-im-n-i-pirogova/2011/12/downloads/ru/030023-120720111211.; Fauchier L., Potpara T. Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice. Thromb Haemost. 2020;120(1):5–7. https://doi.org/10.1055/s-0039-1696646.; Pikija S., Sztriha L.K., Sebastian Mutzenbach J., Golaszewski S.M., Sellner J. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. CNS Drugs. 2017;31(9):747–757. https://doi.org/10.1007/s40263-017-0460-x.; Kermer P., Eschenfelder C.C., Diener H.C., Grond M., Abdalla Y., Althaus K. et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection. Int J Stroke. 2017;12(4):383–391. https://doi.org/10.1177/1747493017701944.; Šaňák D., Jakubíček S., Černík D., Herzig R., Kunáš Z., Mikulík R. et al. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A RealWorld Clinical Experience. J Stroke Cerebrovasc Dis. 2018;27(9):2479–2483. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.004.; Glund S., Moschetti V., Norris S., Stangier J., Schmohl M., van Ryn J. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–951. https://doi.org/10.1160/TH14-12-1080.; Pollack C.V. Jr, Reilly P.A., van Ryn J., Eikelboom J.W., Glund S., Bernstein R.A. et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med. 2017;377(5):431–441. https://doi.org/10.1056/NEJMoa1707278.; Sarode R., Milling T.J. Jr, Refaai M.A., Mangione A., Schneider A., Durn B.L., Goldstein J.N. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243. https://doi.org/10.1161/CIRCULATIONAHA.113.002283.; Goldstein J.N., Refaai M.A., Milling T.J. Jr, Lewis B., Goldberg-Alberts R., Hug B.A., Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–2087. https://doi.org/10.1016/S0140-6736(14)61685-8.; Steiner T., Poli S., Griebe M., Hüsing J., Hajda J., Freiberger A. et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566–573. https://doi.org/10.1016/S1474-4422(16)00110-1.; https://www.aterotromboz.ru/jour/article/view/257